Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC
Image: Merck’s KEYTRUDA anti-PD-1 therapy. Photo: courtesy of Merck Sharp & Dohme Corp.
Image: Merck’s KEYTRUDA anti-PD-1 therapy. Photo: courtesy of Merck Sharp & Dohme Corp.